Novo Nordisk Semaglutide Implant Signals Delivery Boom
Could the Novo Nordisk Semaglutide Implant solve one of obesity treatment’s biggest problems: patients quitting before the drug can work?
Novo Nordisk Competition -2.3% as GLP-1 Pressure Builds
Can Novo Nordisk Competition derail the obesity leader’s comeback before oral Wegovy and Medicare access have a chance to matter?
Novo Nordisk Share Repurchase -2.5% Warning for Bulls
Is Novo Nordisk using its buyback to signal confidence, or to steady nerves as competition and cyber risks unsettle investors?
Novo Nordisk Share Repurchase Drives a 6.4% Rally
Can Novo Nordisk’s massive buyback and Wegovy pill momentum outweigh a fresh cyber threat and keep this rally alive?
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave?